Interleukin Genetics Announces Changes in Senior Management
07/26/2005
Interleukin Genetics Announces Changes in Senior Management
WALTHAM, MA – JULY 26, 2005 – Interleukin Genetics, Inc. (OTCBB:ILGN) announced today that Fenel Eloi, the Company’s Chief Financial Officer and Chief Operating Officer has resigned for personal reasons, effective August 15, 2005. John McCabe, currently the Company’s controller, has been named interim Chief Accounting Officer, effective upon the same date. Philip R. Reilly, MD, JD, Chief Executive Officer of Interleukin Genetics, will act as interim Chief Operating Officer. “Since 2000, Fenel Eloi has served Interleukin Genetics with distinction. We wish him well in his future endeavors”, said Dr. Reilly.
About Interleukin
Interleukin Genetics is a biotechnology company focused on developing personalized health products. The company uses functional genomics to help in the development of risk assessment tests, pharmacogenetic tests, nutritional and therapeutic products based on the genetic variations in people. Interleukin's current programs focus on cardiovascular disease, osteoporosis, periodontal disease and weight management. Interleukin expects that these programs will lead to products that will personalize the selection of nutritional and therapeutic products and enable consumers to manage their health care. For more information about Interleukin and its ongoing programs, please visit http://www.ilgenetics.com.
Certain statements contained herein are “forward-looking” statements including statements regarding filing a 2004 Form 10-K/A and delisting of the company’s common stock. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in our annual report on Form 10-K, our quarterly reports on Form 10-Q and in other filings made by us with the Securities and Exchange Commission. We disclaim any obligation or intention to update these forward-looking statements.
For Interleukin Genetics:
Philip R. Reilly, MD, JD
(781) 398-0700